All In Biotech

Drug Trial Radar · NCT06149663

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Expanded Access Treatment with LP352 for Patients with Developmental and Epileptic Encephalopathies (DEEs) Who Successfully Completed an LP352 Clinical Trial (Intermediate-Size EAP)

Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Longboard PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 29, 2023

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 2 years, up to 65 years

Summary

As written by the sponsor on the registry.

This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs. The EAP study will allow continued treatment with LP352 for eligible participants diagnosed with treatment resistant DEEs who successfully completed an LP352 Clinical Trial (Enrollment by Invitation) or an immediate family member who has the exact same gene mutation resulting in the same DEE epilepsy syndrome phenotype or a patient who previously participated in the lorcaserin EAP.

Conditions

  • Dravet Syndrome
  • Lennox Gastaut Syndrome
  • Developmental and Epileptic Encephalopathies

Interventions

  • LP352Drug

    LP352 will be administered as a liquid either orally or through a G-tube or Percutaneous Endoscopic Gastrotomy (PEG) tube.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Rancho Research Institute

    Downey, California · Available

  • University of California Los Angeles (UCLA)

    Los Angeles, California · Available

  • University of California Benioff Childrens Hospital

    San Francisco, California · Available

  • Colorados Childrens Hospital

    Aurora, Colorado · Available

  • Northwest Florida Clinical Research Group

    Gulf Breeze, Florida · Available

  • Research Institute of Orlando

    Orlando, Florida · Available

  • University of Southern Florida

    Tampa, Florida · Available

  • Hawaii Pacific Neuroscience

    Honolulu, Hawaii · Available

  • Northwestern Medicine Feinberg School of Medicine

    Chicago, Illinois · Available

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland · Available

  • Corewell Health

    Grand Rapids, Michigan · Available

  • Washington University School of Medicine

    St Louis, Missouri · Available

  • New York University (NYU)

    New York, New York · Available

  • Lenox Hill Hospital

    New York, New York · Available

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Available

  • Providence Brain & Spine

    Portland, Oregon · Available

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Available

  • Children's Neuro Consultants of Austin

    Austin, Texas · Available

  • University of Utah

    Salt Lake City, Utah · Available

  • Austin Hospital, Heidelberg

    Heidelberg, Melbourne, Australia · Available

  • Alfred Hospital

    Melbourne, Melbourne, Australia · Available

  • Children's Health Queensland Hospital and Health Service,

    South Brisbane, Queensland, Australia · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.